(Q37937859)

25 August 2017

1 reference

title

The role of targeted therapy in ovarian cancer (English)

1 reference

25 August 2017

1 reference

1

Susana Banerjee

1 reference

25 August 2017

Stan Kaye

2

1 reference

25 August 2017

1 September 2011

1 reference

European Journal of Cancer

25 August 2017

1 reference

25 August 2017

47 Suppl 3

1 reference

25 August 2017

S116-30

1 reference

25 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

The biology of ovarian cancer: new opportunities for translation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

The future of targeted therapies in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Functional significance of VEGFR-2 on ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Making the best of PARP inhibitors in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Mutation of the PIK3CA gene in ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Activation of hedgehog signaling is not a frequent event in ovarian cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Predicting benefit from anti-angiogenic agents in malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970155-1

7 January 2021

10.1016/S0959-8049(11)70155-1

Identifiers

DOI

1 reference

release_xjkoms5emvdcpch7t75c77cxm4

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xjkoms5emvdcpch7t75c77cxm4

24 November 2022

mapped directly with Wikidata item

PubMed ID

21943965

1 reference

PubMed ID

21943965